MedTrace Logo

Biomarkers for Endometriosis

NCT07713797 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-08-03

No results posted yet for this study

Summary

Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, often causing pain and infertility. Currently, endometriosis can only be definitively diagnosed through invasive procedures like laparoscopy and biopsy.

The purpose of this study is to investigate whether the proteins Synuclein Gamma (SNCG) and B-Cell Lymphoma 6 (BCL6), measurable in blood and menstrual fluid, can serve as non-invasive biomarkers to diagnose or monitor endometriosis.

Conditions

Interventions

DIAGNOSTIC_TEST

SNCG Protein

Synuclein gamma (SNCG), a member of the synuclein family of neuronal proteins, is involved in cellular proliferation by interacting with the mitotic checkpoint kinase BubR1, and inhibiting its regulatory role on cellular proliferation. During the last decade, several studies have demonstrated that SNCG is correlated with poor outcome of breast cancer, ovarian cancer, colon cancer and pancreatic cancer. Interestingly, SNCG has previously been shown to have elevated expression ranging from 5- to 53-fold in ovarian endothelial cells of endometriosis lesions compared with eutopic endometrium from the same individual.

DIAGNOSTIC_TEST

BCL-6 Protein

B-Cell Lymphoma 6 (BCL6) protein is encoded by the BCL6 oncogene and is a zinc finger transcription factor that regulates the transcription of signal transducer and activators of transcription (STAT)-dependent IL-4 responses of B-cells. Previously, BCL6 was shown to express in the endometrial epithelial cells and B-cells in lymph node germinal centers. In addition, over-expression of BCL6 has been reported in endometrial biopsies and has been linked to the progesterone resistance and pathogenesis of endometriosis

Sponsors & Collaborators

  • Trio Fertility

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-16
Primary Completion
2027-01-01
Completion
2027-09-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07713797 on ClinicalTrials.gov